INTRODUCTION

Renal angiomyolipoma is a common benign tumour characterized by abnormal blood vessels, smooth muscles, and mature adipose tissue (1). Most of renal angiomyolipomas are small in size and asymptomatic. Angiomyolipoma of the kidneys appears in 0.3–3% of the general population (2). One of the variants of renal angiomyolipoma is epithelioid angiomyolipoma (EAML). It is a very rare tumour, which has been recognized as a mesenchymal tumour in the 2016 World Health Organization classification of renal tumours (3). EAML involves the kidney in most of the cases but can be found in different organs, such as the liver, lungs, the pancreas, and the bladder (4, 5). Middle-aged females have the highest incidence of renal EAML (6). EAML can occur sporadically or as a part of a tuberous sclerosis complex. Classic angiomyolipomas are usually found incidentally on imaging studies and are relatively easy to identify because of the fat component in the tumour, but epithelioid variants of angiomyolipomas are tricky as they mimic various neoplasms (7). Epithelioid angiomyolipomas usually have a high percentage of epithelioid cells (at least 80%) and have a malignancy potential as a significant number of cases have been associated with malignant EAML behaviour (8, 9). Although EAML is not always malignant, the first fatal case of this tumour was reported in 1994 by Martignoni et al. (10).

Clinically, EAML has similar symptoms to those of renal cell carcinoma and remains asymptomatic until the late stages of the disease. Presenting symptoms include: body weight loss, haematuria, abdominal pain, and cough in the advanced disease (11). In addition, patients with EAML frequently express lumbar pains (12). EAML should be taken into consideration by clinicians if the patient is of young age and the renal tumour is large in size (1).

CASE

We report a 40-year-old male patient, whose ultrasound showed a 41 × 40 mm cystic mass in the upper pole of the left kidney. Non-contrast enhanced MRI was carried out and confirmed a 43 × 40 × 40 mm heterogeneous tumour in the upper pole of the left kidney without metastasis (Fig. 1a, b, c). The patient was asymptomatic and the physical examination was within normal limits. Due to the size of the tumour and its potential for malignancy, left partial nephrectomy was performed. The histological analysis showed a tumour that contained large polygonal cells with eosinophillic cytoplasm and polymorphic nuclei; it also showed invasion of the capsule of the kidney and of the surrounding fatty tissue (Fig. 2, 3). The centre of the tumour had an area of necrosis and an area of haemorrhage in it (Fig. 4). The margins were free of tumour. Immunohisto chemical analysis showed HMB45+ 90%, SMA+ 5%, S100-, PanCk-, Synapt-, and the final diagnosis came back as epithelioid angiomyolipoma (Fig. 5a, b). The patient had a yearly follow-up CT scans for six years with the last CT in 2019. Through the years, no recurrence and progression was observed.

Fig. 1
Non-contrast MRI T2 and T1 weighted images. (a) T2 image shows left kidney heterogenous mass (arrow). (b) in-phase image shows hyperintensity (arrow). (c) out-of-phase image shows decreased siganla intensity, indicating microscopic fat (arrow)

Fig. 2
Tumour composed by large polygonal epithelioid cells with abundant eosinophilic granular cytoplasm. HE ×216

Fig. 3
Tumour cells exhibit large irregular nuclei and prominent nucleoli. HE ×400

Fig. 4
General view: encapsulated solid tumour with necrotic centre. HE ×70

Fig. 5
Immunohistochemical stainings show positive reactions against smooth muscle actin (a) and HMB45 (b)

DISCUSSION

Diagnosis of renal angiomyolipoma is considered to be relatively easy because of the presence of fatty cells is found (13). On the other hand, the epithelioid type of angiomyolipoma is challenging in most cases as it can mimic a majority of neoplasms, especially renal cell carcinoma (12). In our case, the tumour was first considered to be renal cell carcinoma and the diagnosis of epithelioid angiomyolipoma was only later confirmed by the histological analysis. There are several diagnostic tools that aid in diagnosing EAML of the kidney, including ultrasound, computer tomography, and magnetic resonance imaging. Contrast-enhanced ultrasound imaging may be beneficial (6). Even with all the advanced techniques in the medical field, renal EAMLs can still be challenging to diagnose, so the combination of various diagnostic tools and histological examination is very important.

Histologically, the proliferation of epithelioid cells and granular cytoplasm of eosinophils is observed (14). Because of its malignant behaviour, factors which determine the risk of malignancy in patients presenting with EAML were searched for (15). There are no definite histological criteria for malignancy except distant metastases, which confirm malignant EAML (12). However, few factors (a high percentage of epithelioid cells, marked atypia and large diameter of the mass) have been associated with EAML malignancy by Jun Lei et al. (16). In his study, four characteristics were found significant in predicting malignant EAML behaviour: tumour size >9 cm, tumour thrombus formation in the vein, epithelioid cells >70% or atypia cells >60%, and necrosis. (16) In a case by Amine Bani et al. necrosis, high mitosis index, marked atypia, vascular involvement, and predominant component of epithelioid cells were associated with malignancy and tumour progression (12). Recent studies by Jun Lei et al. demonstrated the role of HMB45 biomarker in predicting EAML malignancy. All 43 cases in the study presented HMB45-positive. Other markers, such as Ki-67, which were thought to serve as an antigen to indicate EAML malignancy, were proved to be less sensitive compared to HMB45 as only 10 out of 43 cases were Ki-67 positive (16). In our case, the tumour was positive for HMB45 biomarker, as well as SMA. Defects in genes also play a role in the development of epithelioid angiomyolipoma. Malignancy potential might be related to a mutation in p53 gene, as it was described in a few articles (13, 17). A mutation in TSC1 and TSC2 genes have been linked to malignant behaviour of epithelioid angiomyolipomas (16). Missense, non-sense, frame-shift, and splice-site mutations among the 41 coding exons are included in the mutation of TSC2 gene (18). Gene deficiencies in chromosome band 16p13 and clonal chromosomal aberrations were reported by Kattar et al. (19). Defining and systematizing specific EAML malignancy criteria and biomarkers is important to determine patient long term prognosis and to appoint right treatment, so further studies are needed.

For patients with EAML, one of the treatment options is chemotherapy, as EAML is considered to be chemosensitive. Reports of response to the treatment with doxorubicin, dacarbazine, ifosfamide and cisplastin have been published (14). Treatment with mTOR inhibitors, such as everolimus was found to be effective, especially in more complicated cases with malignant EAML behavior, recurrent or unresectable cases (16, 20). Although there is a possibility and positive feedback from systemic treatment, because of its malignant nature, surgical treatment remains as a gold standard for EAML. A study by Kun-Han Lee et al. suggests surgery as main treatment for suspicious renal EAML (1).

Partial nephrectomy is also recommended as first choice treatment for small tumours that are located in the peripheral area of the kidney (17). Nephron-sparing surgery is one of the best treatment choice for classing renal angiomyolipomas when surveillance or conservative treatment is contraindicated (21). According to the literature, most cases of renal AML require adjuvant treatment for relapse and progression (22, 23).

Recurrences of EAML after partial nephrectomy are also possible and have to be taken into consideration, as radical nephrectomy or systemic treatment might be required (24). In the case above, a recurrence of EAML of the kidney was found three years after partial nephrectomy. In our case, partial nephrectomy was successfully performed for a tumour slightly over 4 cm in size and after the diagnosis of renal EAML the patient was observed instead of using systemic treatment and had yearly followup CTs were carried out for up to 6 years as there still was malignancy potential . No progression of the tumour or metastases were observed and no systemic treatment was required. This shows the importance of early diagnosis and treatment of patients with renal EAML, as there is a lack of case reports of this variant of tumour and no guidelines are provided.

CONCLUSIONS

The usual treatment for renal EAML is radical nephrectomy and the use of systemic treatment in case of advanced disease. Early diagnosis with partial nephrectomy can be performed with yearly followup and no systemic treatment is required.

References

1. Lee K-H, Tsai H-Y, Kao Y-T, Lin H-C, Chou Y-C, Su S-H, et al. Clinical behavior and management of three types of renal angiomyolipomas. J Formos Med Assoc. 2019 Jan 1; 118(1, Part 1): 162–9.

2. Andersen PE, Thorlund MG, Wennevik GE, Pedersen RL, Lund L. Interventional treatment of renal angiomyolipoma: immediate results and clinical and radiological follow-up of 4.5 years. Acta Radiol Open [Internet]. 2015 Jul 13 [cited 2019 Nov 7]; 4(7). Available from: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC4548745/

3. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs – Part A: Renal, penile, and testicular tumours. Eur Urol. 2016; 70(1): 93–105.

4. Liang W, Xu S, Chen F. Malignant perivascular epithelioid cell neoplasm of the mediastinum and the lung: one case report. Medicine (Baltimore). 2015 Jun; 94(22): e904.

5. Lee SY, Kim B. Epithelioid angiomyolipoma of the liver: a case report. Clin Mol Hepatol. 2017 Mar; 23(1): 91–4.

6. Zhu J, Li H, Ding L, Cheng H. Imaging appearance of renal epithelioid angiomyolipoma: A case report and literature review. Medicine (Baltimore). 2018 Jan; 97(1): e9563.

7. Mete O, van der Kwast TH. Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intra-abdominal neoplasms. Arch Pathol Lab Med. 2011 May; 135(5): 665–70.

8. JN E, G S, J E, I S. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs [Internet]. [cited 2019 Nov 6]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Pathology-And-Genetics-Of-Tumours-Of-The-UrinarySystem-And-Male-Genital-Organs-2004

9. Nese N, Martignoni G, Fletcher CD, Gupta R, Pan C-C, Kim H, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol. 2011 Feb; 35(2): 161–76.

10. Martignoni G. Renal epithelioid oxyphilic neoplasm (REON): A pleomorphic monophasic variant of renal angiomyolipoma. Int J Surg Pathol. 1995; 2: 539.

11. Chuang CK, Lin HCA, Tasi HY, Lee KH, Kao Y, Chuang FL, et al. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma. Int Urol Nephrol. 2017 Sep; 49(9): 1527–36.

12. Bani MA, Laabidi B, Rejeb SB, Khiari R, Bouziani A, Msakni I. A rare highly aggressive tumor of the kidney: The pure epithelioid angiomyolipoma. Urol Case Rep. 2018 Mar 13; 18: 52–3.

13. He W, Cheville JC, Sadow PM, Gopalan A, Fine SW, Al-Ahmadie HA, et al. Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors. Mod Pathol. 2013 Oct; 26(10): 1355–64.

14. Park HK, Zhang S, Wong MKK, Kim HL. Clinical presentation of epithelioid angiomyolipoma. Int J Urol Off J Jpn Urol Assoc. 2007 Jan; 14(1): 21–5.

15. Lei JH, Liu LR, Wei Q, Song TR, Yang L, Yuan HC, et al. A four-year follow-up study of renal epithelioid angiomyolipoma: a multi-center experience and literature review. Sci Rep. 2015 May 5; 5: 10030.

16. Espinosa M, Roldán-Romero JM, Duran I, de Álava E, Apellaniz-Ruiz M, Cascón A, et al. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation. BMC Cancer. 2018 May 15; 18(1): 561.

17. Tsai H-Y, Lee K-H, Ng K-F, Kao Y-T, Chuang C-K. Clinicopathologic analysis of renal epithelioid angiomyolipoma: Consecutively excised 23 cases. Kaohsiung J Med Sci. 2019 Jan; 35(1): 33–8.

18. Huang Y-J, Jiang Z-P, Chen Y-P, Wu J-Q, Huang J-L, Chen Y-Q, et al. Malignancy of renal angiomyolipoma from tuberous sclerosis complex with TSC2 mutation. Chin Med J (Engl). 2019 Jan 5; 132(1): 103–5.

19. Kattar MM, Grignon DJ, Eble JN, Hurley PM, Lewis PE, Sak WE, et al. Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization: Evidence for clonal origin. Hum Pathol. 1999 Mar 1; 30(3): 295–9.

20. Shitara K, Yatabe Y, Mizota A, Sano T, Nimura Y, Muro K. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. Jpn J Clin Oncol. 2011 Jun; 41(6): 814–6.

21. Boorjian SA, Frank I, Inman B, Lohse CM, Cheville JC, Leibovich BC, et al. The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. Urology. 2007 Dec 1; 70(6): 1064–8.

22. Liu M-X, Gao J-L, Xu S-B, Guo Z-L. Pulmonary and liver metastases with repeated recurrence of renal epithelioid angiomyolioma after nephrectomy: one case report and literature review. 7.

23. Varma S, Gupta S, Talwar J, Forte F, Dhar M. J Nephrol. Renal epithelioid angiomyolipoma: a malignant disease. 2011 Jan-Feb; 24(1): 18–22.

24. Cibas ES, Goss GA, Kulke MH, Demetri GD, Fletcher CD. Malignant epithelioid angiomyolipoma (‘sarcoma ex angiomyolipoma’) of the kidney: a case report and review of the literature. Am J Surg Pathol. 2001 Jan; 25(1): 121–6.

Notes

Información adicional

CONFLICT OF INTEREST: The authors declare that there is no conflict of interest regarding the publication of this article.